Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
MSI-H/dMMR
Cancer:
Solid Tumor
Drug:
Bavencio (avelumab)
(
PD-L1 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Source:
clinicaltrials.gov
Title:
K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor
Excerpt:
Meet at least one of the following requirements; A. PD-L1 positive by IHC or B. EBV positive by ISH or C. MSI-H by IHC or D. POLE mutation E. POLD1 mutation
Trial ID:
NCT03491345
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login